Rare Oral Mucosal Manifestations of Hydroxyurea Therapy in Chronic Myeloid Leukemia
Journal: Haematology International Journal (HIJ) (Vol.1, No. 2)Publication Date: 2017-10-27
Authors : Deena Mudawi Abdulqadir J Nashwan Amna Gameel Shehab Fareed Mohammad Abdulla; Mohamed A Yassin;
Page : 1-2
Keywords : Rare oral mucosal; Chronic myeloid leukemia; Hydroxyurea;
Abstract
Chronic myeloid leukemia (CML), is myeloproliferative neoplasm, that accounts for 15-20% of all leukemia's in adults, resulting from reciprocal translocation between the long arms of chromosomes 9 and 22(Philadelphia chromosome), producing BCR-ABL oncogene fusion, which is currently targeted by tyrosine kinase inhibiters (TKIs), but still Hydroxyurea (HU) usedin chronic myeloid leukemia, its role as cytoreduction and as bridging therapy before starting tyrosine kinase inhibitors (TKI). There are several recognized side effects of hydroxyurea, such as cutaneous abnormalities and here we report rare mucous manifestations of hydroxyurea.
Other Latest Articles
- THE APPLICATION OF THE FMEA METHOD IN THE SELECTED PRODUCTION PROCESS OF A COMPANY
- THE PROCESS APPROACH TO SERVICE QUALITY MANAGEMENT
- Cost-Effectiveness of Idelalisib-Rituximab for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia
- Herpes Zoster Infection in Patient with Chronic Myeloid Leukemia on Imatinib
- Lymphoma without Peripheral Lymphadenopathy: An Approach to Definitive Diagnosis by Flowcytometry
Last modified: 2018-06-05 21:03:38